Fibronostics to Present LIVERFASt Data at DDW 2026

Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on LIVERFASt at the upcoming DDW 2026 conference.

Fibronostics to Present New LIVERFASt Data at EASL Congress 2026

Fibronostics is pleased to announce that new data on LIVERFASt™, its non-invasive blood-based diagnostic test for liver disease, will be shared at the EASL Congress 2026.

Beyond Accuracy: Why LIVERFASt Redefines Non-Invasive Testing for MASLD and MASH

Non-invasive tests (NITs) have transformed how we identify and manage metabolic liver disease. Yet as MASLD and MASH prevalence continues to rise, continued innovation is critical.

Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease

Aim: This study evaluates the diagnostic performance of the novel blood-based device, LIVERFASt, to detect fibrosis stages in patients with metabolic dysfunction-associated steatotic liver disease.

Fibronostics to Present at MASH-TAG 2026 Conference

Fibronostics is excited to announce our participation in the MASH-TAG 2026 Conference, held from January 8-10, 2026, in beautiful Deer Valley.

Fibronostics Reaffirms Commitment to Quality with ISO 13485

At Fibronostics, our mission is built on a foundation of precision and trust. We are proud to announce that we have achieved ISO 13485 certification.

Turmeric & Liver Health: Curcumin’s Real Impact on Fatty Liver

Turmeric has long held a place in traditional wellness, but curcumin, its active compound, is now capturing clinical interest due to its effects on fatty liver.

Bridging the Gap: Liver Health in Diabetes Care

If you’re managing type 2 diabetes, it’s easy to focus on blood sugar numbers and overlook liver health, a critical element of comprehensive care.

Non-Invasive Initiation & Monitoring of Resmetirom (RT) Therapy Using LIVERFASt, FIB-4, and VCTE in MASH Patients

The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom (RT) therapy in patients with metabolic dysfunction-associated steatotic liver disease.

Liver & Pancreas Connection: Why Early Detection Matters in Metabolic Health

Understanding the connection between the liver and pancreas is imperative for recognizing metabolic health and addressing conditions like diabetes.